Adverum reports increased third quarter loss

Adverum Biotechnologies reported an increase in its third quarter net loss to $21 million, or $0.34 per share, in 2018 compared with a net loss of $13.8 million, or $0.32 per share, in 2017’s third quarter.
Revenue increased to $0.8 million from $0.5 million, which Adverum attributed to research services provided to Editas under a collaboration agreement.
Research and development costs increased from $10.3 million in 2017’s third quarter to $14.5 in 2018, mostly related to clinical trial expenses for ADVM-043, clinical trial initiation expenses for ADVM-022, and costs for (Read more...)

Full Story →